Filed in archive
Hay Fever
by ruth on July 24, 2006

"We chose to study short ragweed because it is one of the most prevalent forms of pollen allergy in the United States," says Dr. Bob Esch, Vice President of Research and Development for Greer. "The majority of Americans with seasonal allergic rhinitis are sensitized to short ragweed pollen, so this patient population will be representative of pollen-allergic patients commonly seen in allergy offices.
According to this report, patient recruitment for the trials have already begun at four allergy clinics in the US. See YahooNews to read the full story.
[Photo: American Academy of Allergy, Asthma and Immunology]
Tags:
ragweed
immunotherapy
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/30014
Mr Wong
Vote for Phase IIB Clinical Trials for Sublingual-Oral Immunotherapy for Short Ragweed Allergy:
|
Rating: 6.50 out of 4 vote(s) cast.
|
Response from:
Cathy Reagor
(11/01/06 2:51pm)
Response from:
ruth
(11/02/06 5:22pm)
Hi Cathy. Am not sure whether they're still recruiting for volunteers. You can inquire directly at GreenLabs, if not for this trial, maybe for the next ones. Or check for other ongoing trials for which you may qualify at www.clinicaltrials.gov
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |








Cathy Reagor 406-594-1249